Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial

Category Primary study
JournalANNALS OF ONCOLOGY
Year 2020
This article has no abstract
Epistemonikos ID: 613386ada366b814bf49b08e39e06e500f158887
First added on: Feb 11, 2025